Drs. Sara Ghandehari and Weijia Chua discuss how to best monitor patients when guidelines and protocols vary and more research is needed. Read more
Get to know IASLC’s new Chief Science Officer and learn more about the role she and her team will play in conquering thoracic cancers in the 21st century. Read more
The IASLC seeks the lung cancer community’s input to assess the use of molecular testing—and barriers to its implementation—worldwide. Read more
Drs. Umberto Malapelle, Jarushka Naidoo, Isabelle Opitz, and Noemí Reguart will lead WCLC when it returns to Barcelona September 6-9, 2025. Read more
Other recent regulatory moves include the FDA granting full approval to tepotinib for metastatic NSCLC harboring MET exon skipping alterations and new applications for amivantamab in the US and Europe. Read more
Artificial Intelligence in Thoracic Radiation Oncology: Treatment, Challenges, and Future Directions
+more
In part 2 of our look at AI’s impact on radiotherapy, Grace Lee, MD, Fridolin Haugg, MSc, and Raymond H. Mak, MD, discuss how AI may be leveraged when delivering radiotherapy, including improving our ability to predict treatment response and adverse events. Read more
Projects—including a team science grant, an expanded IASLC Academy, and an international biomarker survey—aim to help the association meet the needs of the global lung cancer community, IASLC leaders say. Read more
The European Commission recently approved adagrasib for KRAS G12C+ non-small cell lung cancer. Additionally, the US FDA has accepted a premarket approval application for tumor treating fields therapy. Read more
The 2024 World Conference on Lung Cancer may still be months away, but with deadlines approaching, now is the time to submit scientific abstracts and applications for the JTO manuscript reviewer workshop. Read more
Research teams with integrated projects focused on curing oncogene-driven lung cancers could receive up to $2.5 million over 4 years. Read more